Trevi Therapeutics (TRVI) Capital Expenditures (2018 - 2026)

Trevi Therapeutics' Capital Expenditures history runs 8 years deep, the most recent figure standing at $102000.0 for Q1 2026.

• In Q1 2026, Capital Expenditures changed N/A year-over-year to $102000.0; the TTM figure through Mar 2026 stood at $121000.0 (changed N/A YoY), while the FY2025 annual figure was $12000.0, down 65.71% from the prior year.
• Capital Expenditures for Q1 2026 stood at $102000.0, up from $12000.0 in the prior quarter.
• The five-year high for Capital Expenditures was $116000.0 in Q4 2022, with the low at $7000.0 in Q4 2024.
• The 5-year median for Capital Expenditures is $31000.0 (2023), against an average of $46750.0.
• The sharpest annual moves came in 2023 and 2024: Capital Expenditures tumbled 81.03% in 2023, then sank 68.18% in 2024.
• Trevi Therapeutics' Capital Expenditures stood at $116000.0 in 2022, then sank by 81.03% to $22000.0 in 2023, then slumped by 68.18% to $7000.0 in 2024, then soared by 71.43% to $12000.0 in 2025, then surged by 750.0% to $102000.0 in 2026.
• Business Quant data shows TRVI's Capital Expenditures at $102000.0 in Q1 2026, $12000.0 in Q3 2025, and $7000.0 in Q4 2024.